急性髓系白血病中维奈克拉耐药性的临床与生物学见解
维奈克拉为口服BCL-2抑制剂,与低甲基化药物联合是老年及不适合强化治疗急性髓系白血病的标准治疗方案,也越来越多与强化化疗联合用于一线和复发治疗。本综述总结维奈克拉细胞毒作用的已知机制、耐药通路与特定突变的关联,并为当前及未来临床试验中的新药联合提供依据。
要点
- 维奈克拉联合低甲基化药物是老年及不适合强化治疗急性髓系白血病的当前标准治疗方案。
- 某些遗传学异常与维奈克拉敏感相关,另一些与耐药相关,耐药可在治疗中出现并导致疾病复发。
- 综述总结维奈克拉抑制BCL-2介导凋亡及影响细胞代谢的机制,并阐述其与耐药和特定突变的关联。
核心结论
- 某些遗传学异常与维奈克拉敏感相关,另一些与耐药相关,耐药可在治疗中出现并导致疾病复发。
- 综述为当前及未来临床试验中的新药联合提供依据。
研究设计与样本
- 本文为综述,总结维奈克拉细胞毒作用的已知机制及其与耐药和特定突变的关联。
主要发现
- 维奈克拉细胞毒作用涉及抑制BCL-2介导的凋亡及其对细胞代谢的影响。
- 这些通路与维奈克拉耐药相关,并与特定突变相关。
- 维奈克拉与低甲基化药物联合是老年及不适合强化治疗患者的当前标准治疗方案。
- 维奈克拉也越来越多与强化化疗方案联合用于一线和复发治疗。
临床怎么用
- 维奈克拉联合低甲基化药物是老年及不适合强化治疗急性髓系白血病的当前标准治疗方案。
- 维奈克拉也越来越多与强化化疗方案联合用于一线和复发治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Venetoclax, an oral BCL-2 inhibitor, has been widely incorporated in the treatment of acute myeloid leukaemia. The combination of hypomethylating agents and venetoclax is the current standard of care for elderly and patient's ineligible for aggressive therapies. However, venetoclax is being increasingly used with aggressive chemotherapy regimens both in the front line and in the relapse setting. Our growing experience and intensive research demonstrate that certain genetic abnormalities are associated with venetoclax sensitivity, while others with resistance, and that resistance can emerge during treatment leading to disease relapse. In the current review, we provide a summary of the known mechanisms of venetoclax cytotoxicity, both regarding the inhibition of BCL-2-mediated apoptosis and its effect on cell metabolism. We describe how these pathways are linked to venetoclax resistance and are associated with specific mutations. Finally, we provide the rationale for novel drug combinations in current and future clinical trials.
引用
- Nachmias B, Aumann S, Haran A, et al. Venetoclax resistance in acute myeloid leukaemia-Clinical and biological insights. Br J Haematol. 2024. PMID: 38296617. doi:10.1111/bjh.19314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。